Covered recipient · General Payments record
SANJAY CHABRA
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$500,130.81
668 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $334,811.00 | 128 |
| Travel and Lodging | $76,295.54 | 186 |
| Consulting Fee | $66,694.25 | 23 |
| Food and Beverage | $13,041.94 | 326 |
| Honoraria | $9,187.50 | 3 |
| Education | $59.99 | 1 |
| Gift | $40.59 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $114,633.10 | 158 |
| ABBVIE INC. | $108,507.73 | 132 |
| AstraZeneca Pharmaceuticals LP | $88,827.11 | 77 |
| GENZYME CORPORATION | $31,385.12 | 39 |
| UCB, Inc. | $31,364.45 | 47 |
| GlaxoSmithKline, LLC. | $29,342.10 | 25 |
| Mallinckrodt Hospital Products Inc. | $20,933.87 | 34 |
| Lilly USA, LLC | $18,984.05 | 18 |
| Novartis Pharmaceuticals Corporation | $18,953.18 | 37 |
| Aurinia Pharma U.S., Inc. | $13,730.79 | 24 |
| ANI Pharmaceuticals, Inc. | $11,763.48 | 23 |
| PFIZER INC. | $9,631.89 | 11 |
| Janssen Biotech, Inc. | $809.18 | 5 |
| SOBI, INC | $517.04 | 9 |
| Actelion Pharmaceuticals US, Inc. | $338.41 | 8 |
| Organon Llc | $134.39 | 7 |
| E.R. Squibb & Sons, L.L.C. | $56.03 | 2 |
| Cardinal Health Inc | $42.85 | 1 |
| Alexion Pharmaceuticals, Inc. | $42.79 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $39.45 | 2 |
| Ultragenyx Pharmaceutical Inc. | $33.17 | 2 |
| Fresenius Kabi USA, LLC | $30.04 | 2 |
| Teva Pharmaceuticals USA, Inc. | $16.77 | 1 |
| Genentech USA, Inc. | $13.82 | 1 |
Page 2 of 14; records 51–100 of 668 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SANJAY CHABRA
NPI 1316916125 · CMS profile ID 241418
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
EL PASO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 14; records 51–100 of 668 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1316916125?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SANJAY CHABRA, NPI 1316916125, CMS profile ID 241418. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 14; records 51–100 of 668 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316916125?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). SANJAY CHABRA, NPI 1316916125, CMS profile ID 241418. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 14; records 51–100 of 668 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316916125?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- SANJAY CHABRA, NPI 1316916125, CMS profile ID 241418, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 14; records 51–100 of 668 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1316916125?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
668 matching records · $500,130.81 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 668.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $4,600.00 | 11/12/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103132655 | CMS |
| Amgen Inc. | $3,300.00 | 11/12/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487578 | CMS |
| ABBVIE INC. | $26.05 | 11/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103433580 | CMS |
| Amgen Inc. | $21.69 | 11/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117523541 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.48 | 11/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104277983 | CMS |
| Amgen Inc. | $150.00 | 11/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487145 | CMS |
| GlaxoSmithKline, LLC. | $15.82 | 11/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116422093 | CMS |
| GlaxoSmithKline, LLC. | $9.94 | 11/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116511605 | CMS |
| Mallinckrodt Hospital Products Inc. | $6,720.00 | 11/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145054966 | CMS |
| ABBVIE INC. | $4,025.00 | 11/06/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103144317 | CMS |
| ABBVIE INC. | $2,875.00 | 11/06/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103144319 | CMS |
| ABBVIE INC. | $96.74 | 11/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103433576 | CMS |
| ABBVIE INC. | $4.08 | 11/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103433578 | CMS |
| ABBVIE INC. | $1,707.47 | 11/06/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104179726 | CMS |
| Organon Llc | $16.60 | 11/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136187842 | CMS |
| Amgen Inc. | $13.52 | 11/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487514 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,074.00 | 11/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104296634 | CMS |
| Amgen Inc. | $24.31 | 11/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117523511 | CMS |
| ABBVIE INC. | $24.51 | 11/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103433574 | CMS |
| Amgen Inc. | $531.23 | 11/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487612 | CMS |
| Mallinckrodt Hospital Products Inc. | $20.57 | 10/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145054945 | CMS |
| Mallinckrodt Hospital Products Inc. | $668.96 | 10/31/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145054949 | CMS |
| Mallinckrodt Hospital Products Inc. | $218.48 | 10/31/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145054953 | CMS |
| Mallinckrodt Hospital Products Inc. | $24.47 | 10/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145054957 | CMS |
| Mallinckrodt Hospital Products Inc. | $111.68 | 10/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145054961 | CMS |
| PFIZER INC. | $3,000.00 | 10/31/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131402153 | CMS |
| Amgen Inc. | $3,300.00 | 10/30/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487567 | CMS |
| Amgen Inc. | $14.84 | 10/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487590 | CMS |
| Amgen Inc. | $152.02 | 10/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487617 | CMS |
| Amgen Inc. | $24.59 | 10/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487549 | CMS |
| Ultragenyx Pharmaceutical Inc. | $18.43 | 10/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153280687 | CMS |
| Amgen Inc. | $825.00 | 10/28/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487572 | CMS |
| Amgen Inc. | $853.17 | 10/28/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487608 | CMS |
| Amgen Inc. | $20.05 | 10/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117523509 | CMS |
| UCB, Inc. | $23.05 | 10/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143264031 | CMS |
| UCB, Inc. | $29.61 | 10/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143264036 | CMS |
| Aurinia Pharma U.S., Inc. | $1.14 | 10/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150677655 | CMS |
| Lilly USA, LLC | $1,150.00 | 10/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135375180 | CMS |
| Novartis Pharmaceuticals Corporation | $296.88 | 10/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616841 | CMS |
| Novartis Pharmaceuticals Corporation | $184.51 | 10/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616843 | CMS |
| Novartis Pharmaceuticals Corporation | $7,600.00 | 10/25/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616845 | CMS |
| Novartis Pharmaceuticals Corporation | $5.19 | 10/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616887 | CMS |
| Novartis Pharmaceuticals Corporation | $68.57 | 10/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616897 | CMS |
| Novartis Pharmaceuticals Corporation | $905.39 | 10/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086616899 | CMS |
| Amgen Inc. | $825.00 | 10/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487533 | CMS |
| Novartis Pharmaceuticals Corporation | $223.52 | 10/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155561555 | CMS |
| Amgen Inc. | $21.05 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487505 | CMS |
| Amgen Inc. | $21.48 | 10/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115487542 | CMS |
| ANI Pharmaceuticals, Inc. | $80.00 | 10/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091131415 | CMS |
| ANI Pharmaceuticals, Inc. | $288.95 | 10/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091139770 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $77,380.59 | 12 |
| PY2024 | Principal investigator | $28,318.50 | 8 |
| PY2023 | Principal investigator | $10,226.00 | 5 |
| PY2022 | Principal investigator | $161,148.13 | 3 |
| PY2021 | Principal investigator | $6,420.13 | 1 |
| PY2019 | Principal investigator | $1,587.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
12 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $698.00 | 11/24/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER | Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE | No dispute reported | 06/30/2026 | 1211662768 |
| Principal investigator 1 | Genentech, Inc. | $5,807.01 | 09/22/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | No dispute reported | 06/30/2026 | 1211662761 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,896.08 | 07/23/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER, PA | Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis | No dispute reported | 06/30/2026 | 1185542920 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $2,500.00 | 07/16/2025 | Non-covered Recipient Entity Sanjay Chabra dba Texas Arthritis Center | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243931250 |
| Principal investigator 1 | Genentech, Inc. | $27,105.00 | 07/14/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER | Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE | No dispute reported | 06/30/2026 | 1211662765 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,822.04 | 07/09/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL | No dispute reported | 06/30/2026 | 1190309834 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $845.00 | 05/07/2025 | Non-covered Recipient Entity Sanjay Chabra dba Texas Arthritis Center | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930745 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $5,000.00 | 05/07/2025 | Non-covered Recipient Entity Sanjay Chabra dba Texas Arthritis Center | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930747 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,896.08 | 04/17/2025 | Non-covered Recipient Entity AGA CLINICAL TRIALS | Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis | No dispute reported | 06/30/2026 | 1185542922 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,312.16 | 03/31/2025 | Non-covered Recipient Entity TEXAS ARTHRITIS CENTER | An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1190309832 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $2,535.00 | 03/12/2025 | Non-covered Recipient Entity Sanjay Chabra dba Texas Arthritis Center | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930956 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $964.22 | 01/21/2025 | Non-covered Recipient Entity Texas Arthritis Center, Pa | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) | No dispute reported | 06/30/2026 | 1235993335 |